Skip to content

Proacta's lead drug candidate is a hypoxia targeted small-molecule prodrug designed to improve the outcomes of patients with cancer by targeting cells that are resistant to current treatments, including chemotherapy and radiotherapy. PR104 is being evaluated in two randomized Phase 2 clinical trials in patients with hepatocellular carcinoma and non-small cell lung cancer.

News at Proacta

  • Alta Partners
  • Cancer Society
  • Clarus
  • Delphi Ventures
  • Endeavour Capital
  • GBS
  • Genentech
  • No. 8 Ventures
  • Roche
  • UniServices
  • The University of Auckland